Previous 10 | Next 10 |
SAN DIEGO, CA / ACCESSWIRE / December 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), today announced that the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on December 20, 2023 at 9:00 a.m. Pacific Time has been postponed due to ...
Results Reinforce Efficacy of PF614 as a Next Generation Analgesic with Significant Pain Intensity Reduction PF614 Clinical Data Primes FDA Evaluation and Design of Phase 3 Studies in 2024 SAN DIEGO, CA / ACCESSWIRE / December 14, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensy...
PHOENIX, AZ / ACCESSWIRE / December 11, 2023 / The Stock Day Podcast welcomed Ensysce Biosciences (NASDAQ:ENSC) ("the Company"), a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs.CEO of the Company, Dr. Lynn Kirkpatrick, joined Stock Day host...
2023-12-01 12:52:15 ET Gainers: Neximmune ( NEXI ) +304% . Green Giant ( GGE ) +97% . XBP Europe Holdings ( XBP ) +89% . ShiftPixy ( PIXY ) +47% . Clearmind Medicine ( CMND ) +33% . Elastic N.V ( ESTC ) +34% . Gen...
2023-12-01 08:25:56 ET Losers: Smart for Life ( SMFL ) -38% announces exercise of warrants for $1.5 Million gross proceeds . Ampio Pharmaceuticals ( AMPE ) -34% . Incannex Healthcare ( IXHL ) -34% . Vivos Therapeutics ( VVOS ) -14% . ...
Additional Funding from Investors Validates Company's Mission SAN DIEGO, CA / ACCESSWIRE / November 29, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, announced tod...
Collaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer Treatment SAN DIEGO, CA and STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinica...
~ Enrollment Completion Signifies Critical Progress to Phase 3 of PF614 ~ ~ Trial Results Expected in December 2023 ~ SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying transformative c...
Ensysce Biosciences Inc. (ENSC) is expected to report $-1.06 for Q3 2023
2023-11-09 18:04:56 ET More on Ensysce Biosciences Ensysce Biosciences gets $1.7M note financing Seeking Alpha’s Quant Rating on Ensysce Biosciences Historical earnings data for Ensysce Biosciences Financial information for Ensysce Biosciences ...
News, Short Squeeze, Breakout and More Instantly...
Ensysce Biosciences Inc. Company Name:
ENSC Stock Symbol:
NASDAQ Market:
New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPAR SAN DIEGO, CA / ACCESSWIRE / May 20, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutio...
PF614's Phase 3 Clinical Plans Affirm the Path to Regulatory Approval FDA Breakthrough Therapy Designation of PF614-MPAR Expedites Clinical Program SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmac...
~ Dr. Kirkpatrick Leads the Company's Unique Response to Effectively Reduce Prescription Drug Overdose and Abuse ~ SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative...